

*Samira Ashmawi*  
*Tarek Safwat*  
*17/11/1996*  
*16/11/1996*

**STUDY OF POTASSIUM LEVEL IN CHRONIC  
OBSTRUCTIVE PULMONARY DISEASES  
RECEIVING ORAL VERSUS  
INHALED B<sub>2</sub>-AGONISTS**

Thesis Submitted for the Partial Fulfillment of the  
Master Degree in Chest Diseases

By

**Mostafa Mahmoud Ahmed**

M.B., B.Ch.

Supervised by

*512, 814*  
*M - M*  
**Prof. Dr. Tarek Safwat**

Prof. of Chest Diseases

Faculty of Medicine-Ain Shams University

**Prof. Dr. Mohamed Awad Tag El-Din**

Prof. of Chest Diseases

Faculty of Medicine-Ain Shams University

**Prof. Dr. Samiha Ashmawi**

Prof. of Chest Diseases

Faculty of Medicine-Ain Shams University

**Faculty of Medicine  
Ain Shams University  
1996**





بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

**قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا  
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ**

صَدَقَ اللَّهُ الْعَظِيمُ

سورة البقرة الآية ٣٢



## *Acknowledgment*

*First and for most, thanks to ALLAH*

*I would like to express my gratitude and respect to Prof. Dr. Tarek Safwat, Prof. of Chest Diseases, Faculty of Medicine, Ain Shams University, for his kind supervision, encouragement and great help.*

*I would like to present my appreciation and thanks to Prof. Dr. Mohamed Awad Tag El-Din, Prof. of Chest Diseases, Faculty of Medicine, Ain Shams University, for his valuable guidance, continuous help and support.*

*My cordial thanks and appreciation to Prof. Dr. Samiha Ashmawi, Prof. of Chest Diseases, Faculty of Medicine, Ain Shams University, who saved no time in helping me throughout this work and assisted me beyond most wild hopes to present this work.*

*Mostafa Mahmoud*



## **List of contents**

	<b>Page</b>
<b>Introduction and aim of the work</b>	<b>1</b>
<b>Review of literature</b>	<b>2</b>
Chronic obstructive pulmonary diseases (COPD)	2
Clinical features of COPD	12
Short notes on management of COPD	19
Adrenergic agents	27
Potassium metabolism	47
<b>Patients and methods</b>	<b>58</b>
<b>Results</b>	<b>65</b>
<b>Discussion</b>	<b>85</b>
<b>Summary and conclusion</b>	<b>93</b>
<b>Recommendations</b>	<b>94</b>
<b>References</b>	<b>96</b>
<b>Arabic summary</b>	





## List of tables

	Page
Table 1: Pharmacologic effects and pharmacokinetics of sympathomimetic bronchodilators	40
Table 2: Forms and dosage of albuterol	42
Table 3: Presentation of cases	65
Table 4: Mean arterial blood gases	66
Table 5: Kidney function tests	66
Table 6: Liver function tests	66
Table 7: C.B.C.	66
Table 8: Haemoglobin level and ESR	67
Table 9: Pulmonary function tests	67
Table 10: Random blood glucose	68
Table 11: Changes in mean plasma K in group I	70
Table 12: Comparison between baseline K and 1/2 h in group I	71
Table 13: Comparison between baseline K and 3 h in group I	71
Table 14: Changes in mean plasma K in group II	72
Table 15: Comparison between baseline and 1/2 h K level in group II	73
Table 16: Comparison between baseline and 3 h K level in group II	74
Table 17: Comparison between baseline and decline of K level in group I & II	74
Table 18: Comparison between group I & II as regard 1/2 h changes in K level	75
Table 19: Comparison between group I & II as regard 3 h changes in K level	75
Table 20: Comparison between 1/2 h K level in group Ia and 2 h in IIa	76
Table 21: Comparison between 1/2 h K in Ib and 2 h in IIb	76
Table 22: Comparison between 1/2 h K in Ic and 2 h in IIc	77
Table 23: Comparison between fenoterol and salbutamol inhaler on K level after 3 hrs	83
Table 24: Comparison between fenoterol and salbutamol tablets on K level after 3 hs	83
Table 25: Comparison between fenoterol and terbutaline inhaler after 3 hs	83
Table 26: Comparison between fenoterol and terbutaline tablet after 3 hs	84
Table 27: Comparison between salbutamol and terbutaline inhaler after 3 hs	84
Table 28: Comparison between salbutamol and terbutaline tablet after 3 hs	84



## List of figures

	Page
Fig 1: Structure of phenylethylamine and substitutions	31
Fig. 2: Pulmonary function tests	67
Fig. 3: Staging of COPD patients	68
Fig. 4: Changes in mean K level in group I	70
Fig. 5: Changes in mean K level in group II	73
Fig. 6: Mean decline in K after baseline in group I	77
Fig. 7: Mean decline in K after baseline in group I in scale line graph	78
Fig. 8: Mean decline in K after baseline in group II	80
Fig. 9: Mean decline in K after baseline in group II in scale line graph	80



*Introduction  
and  
Aim of the Work*

